Cargando…
Long-term experience in the treatment of α(1)-antitrypsin deficiency: 25 years of augmentation therapy
Although it is often under-recognised, α(1)-antitrypsin deficiency (AATD) represents one of the most common genetic respiratory disorders worldwide. Since the publication of studies in the late 1980s, which demonstrated that plasma-derived augmentation therapy with intravenous α(1)-antitrypsin (AAT)...
Autor principal: | Teschler, Helmut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487776/ https://www.ncbi.nlm.nih.gov/pubmed/25726554 http://dx.doi.org/10.1183/09059180.10010714 |
Ejemplares similares
-
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012) -
Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021) -
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009) -
Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017) -
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)